Myeloma Clinical Trial
Official title:
Phase II Study of High-Dose Topotecan, Cyclophosphamide and Melphalan for the Treatment of Multiple Myeloma
To determine the efficacy of high-dose topotecan, cyclophosphamide and melphalan in patients with Multiple Myeloma.
Patients in this study will have a catheter (a tube) placed in the vein below the collarbone.
Most of the drugs used in the study will be given through the catheter. Blood stem cells will
be collected through this tube also.
Before treatment starts, patients will have a complete physical exam, including blood and
urine tests. A dentist will perform a dental exam either at M.D. Anderson or elsewhere. A
chest x-ray and bone x-rays will be done. An EKG and a heart scan will be done to test heart
function. A breathing test will be done. Patients will also be screened for HIV and
Hepatitis.
Blood stem cells will be collected from patients when white blood cell counts are normal.
This will be after earlier chemotherapy or after a bone marrow growth factor (G-CSF) has been
given. Collecting stem cells takes about 3 hours. It takes from 1 to 6 sessions to get the
needed amount of cells. The process is called apheresis. A machine is attached to the
catheter, and blood is drawn. The machine removes the stem cells from the blood and the blood
is then returned to the body through the catheter. G-CSF is injected under the skin twice a
day during the time the stem cells are collected. The stem cells are stored frozen and will
be used later to help patients recover from the high-dose chemotherapy.
After stem cells are collected, patients will receive high-dose chemotherapy.
Cyclophosphamide is given over 2 hours on Days 1 - 3. Melphalan is given on Days 4 and 5.
Topotecan is given over 30 minutes on Days 1 - 5, right after cyclophosphamide or melphalan.
On Day 6, no drugs are given. On Day 7, some or all of the stem cells will be reinfused.
G-CSF will be given once a day until blood counts return to normal.
Patients must stay in the hospital for the high-dose drug treatment. The length of stay will
be about 3 weeks. Blood tests will be done daily while in hospital, then once a week for the
first month. A bone marrow sample will be taken on Day 30. Blood samples will be taken 4
times in the first year and once a year after that. Thyroid gland tests and a bone marrow
test will be done once a year.
This is an investigational study. Cyclophosphamide, melphalan, and topotecan are approved by
the FDA. Their use together in this study is experimental. All participants will be enrolled
at UTMDACC.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03832127 -
Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients
|
Phase 1 | |
| Completed |
NCT01413178 -
A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
|
Phase 3 | |
| Recruiting |
NCT03641456 -
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
|
Phase 2 | |
| Terminated |
NCT02907073 -
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
|
Phase 1/Phase 2 | |
| Completed |
NCT03135925 -
Feasibility of Pre Transplant Exercise (Pre-habilitation) for Multiple Myeloma Patients Awaiting Autologous Stem Cell Transplantation
|
N/A | |
| Withdrawn |
NCT02114502 -
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
|
Phase 2 | |
| Completed |
NCT00800839 -
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
|
Phase 2 | |
| Completed |
NCT01700608 -
Prospective Observational Study on Plerixafor After Chemotherapy
|
N/A | |
| Completed |
NCT00794261 -
Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma
|
Phase 2 | |
| Completed |
NCT00606437 -
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
|
Phase 1 | |
| Recruiting |
NCT05528887 -
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
|
Phase 1 | |
| Recruiting |
NCT05625971 -
Non-invasive MRD Assessment in Multiple Myeloma
|
||
| Active, not recruiting |
NCT02931942 -
Changing Over Time of Ascorbic Acid After Chemotherapy
|
||
| Active, not recruiting |
NCT05889221 -
Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
|
N/A | |
| Recruiting |
NCT03836690 -
Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation
|
Phase 1 | |
| Active, not recruiting |
NCT02542657 -
Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma
|
Phase 1/Phase 2 | |
| Completed |
NCT01279694 -
Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)
|
Phase 1/Phase 2 | |
| Completed |
NCT01191060 -
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
|
Phase 3 | |
| Terminated |
NCT00983346 -
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
|
Phase 2 | |
| Completed |
NCT00476294 -
Long-Term Follow Up Study for AMD3100 Patients
|
N/A |